|Dr. William V. Williams M.D.||CEO, Pres & Director||218k||N/A||1957|
|Dr. Charles Louis Wiseman FACP, M.D.||Founder, Principal Research Advisor & Member of Scientific Advisory Board||241.14k||N/A||1946|
|Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA||CFO & Corp. Sec.||114.28k||N/A||1973|
|Dr. Miguel A. Lopez-Lago||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Giuseppe Del Priore M.D., M.P.H., MPH||Chief Medical Officer||N/A||N/A||1962|
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.